Catalpol: Multi-Target Iridoid Glycoside for Neuroprotection & Disease Models

Executive Summary: Catalpol, a natural product from Rehmannia and offered by APExBIO (CAS No. 2415-24-9), is an iridoid glycoside with high purity (98%) and robust solubility in water, DMSO, and ethanol (product page). It acts as an inhibitor of NF-κB, EphA2/FAK/Src, and NLRP3 inflammasome pathways, reducing neuroinflammation and oxidative stress (Wang et al. 2022). Catalpol activates pro-survival pathways including TrkB, VEGF-PI3K/AKT, and Sirt6-ERα-FasL, supporting neuroregeneration and angiogenesis. Validated in vivo in ischemic stroke, osteoporosis, and depression models, Catalpol demonstrates dose-dependent efficacy and translational relevance. Typical dosing is 2.5–80 mg/kg/day (i.p., oral, or i.v.), and in vitro use ranges from 2–100 μM, with storage at –20°C for stability.

Biological Rationale

Catalpol is a natural iridoid glycoside, also known as catalpinoside, isolated primarily from the radix of Rehmannia glutinosa (APExBIO). It is classified as a monosaccharide iridoid glycoside and exhibits a broad spectrum of biological activities. Catalpol’s relevance in translational research is supported by its ability to modulate neuroinflammation, oxidative stress, and apoptosis—key contributors to neurological and degenerative diseases (Wang et al. 2022). The neurovascular unit (NVU) integrity is crucial for brain homeostasis and is compromised in conditions such as ischemic stroke, traumatic brain injury, and Alzheimer’s disease. Catalpol’s capacity to restore NVU function underpins its therapeutic potential in multiple preclinical models (see review). This article extends the analysis provided in this prior review by detailing quantitative benchmarks and workflow integration best practices.

Mechanism of Action of Catalpol

Catalpol exerts its effects through specific and multi-modal signaling modulation:

• NF-κB Inhibition: Suppresses NF-κB pathway, reducing pro-inflammatory cytokine expression and neuroinflammation (Wang et al. 2022).
• EphA2/FAK/Src Pathway Inhibition: Blocks this pathway, limiting endothelial dysfunction and vascular inflammation (see mechanistic review).
• NLRP3 Inflammasome Inhibition: Inhibits inflammasome assembly, reducing IL-1β production and microglial activation.
• TrkB Activation: Increases secretion of brain-derived neurotrophic factor (BDNF), supporting neuronal survival and synaptic plasticity.
• VEGF-PI3K/AKT and VEGF-MEK1/2/ERK1/2 Activation: Catalpol upregulates VEGF, activating PI3K/AKT and MEK1/2/ERK1/2 cascades, promoting angiogenesis and neurogenesis (Wang et al. 2022).
• Sirt6-ERα-FasL Pathway: Supports anti-apoptotic and osteoprotective effects.

This article clarifies the molecular targets described in earlier pathway-centric discussions by mapping them to validated in vivo endpoints.

Evidence & Benchmarks

• Catalpol dose-dependently reduces infarct volume in permanent middle cerebral artery occlusion (MCAO) rat models (2.5–10 mg/kg/day i.v., 14 days), with significant improvement in neurological deficit scores (Wang et al. 2022).
• Catalpol treatment promotes angiogenesis and neurogenesis in the ischemic brain, restoring vessel-neuron-astrocyte architecture (Wang et al. 2022).
• VEGF expression is significantly increased after catalpol exposure, with downstream PI3K/AKT and MEK1/2/ERK1/2 pathway activation confirmed in both in vivo and 3D NVU in vitro models (Wang et al. 2022).
• In LPS-induced sepsis-associated encephalopathy and chronic unpredictable mild stress (CUMS) depression models, catalpol reduces neuroinflammatory markers and improves behavioral outcomes (mechanistic review).
• Ovariectomy-induced osteoporosis models show increased bone mass and microarchitecture preservation with catalpol (dose: 5–80 mg/kg/day, oral or i.p., 4–8 weeks) (osteoporosis review).
• Catalpol displays high aqueous solubility (≥25.25 mg/mL) and maintains ≥98% purity under recommended storage, supporting reproducible in vitro and in vivo dosing (APExBIO).

Applications, Limits & Misconceptions

Catalpol is widely validated in the following research domains:

• Neuroprotection research: Models of ischemic stroke, cognitive impairment, and neuroinflammation.
• Osteoporosis animal model: Postmenopausal, ovariectomy-induced bone loss studies (see existing review).
• Liver fibrosis research: Carbon tetrachloride-induced animal models.
• Depression model study: CUMS and LPS-induced behavioral paradigms.

This article updates the translational impact and dosing guidance compared to this prior summary by integrating recent peer-reviewed quantitative endpoints.

Common Pitfalls or Misconceptions

• Not a panacea: Catalpol is not effective in models where neuroinflammation is not a central driver (e.g., purely genetic neurodegeneration models without inflammatory components).
• Species/Strain Differences: Efficacy may vary significantly between rodent strains and is not yet validated in non-human primates.
• Stability concerns: Catalpol solutions are for short-term use only; degradation may occur at room temperature or after repeated freeze–thaw cycles (APExBIO).
• No direct anti-tumor efficacy: Despite pathway overlap, catalpol has not demonstrated validated anti-cancer outcomes in standard tumor xenograft models.
• Limited clinical translation: To date, catalpol has not been tested in large-scale human clinical trials.

Workflow Integration & Parameters

Catalpol (N1352) is supplied by APExBIO with a purity of 98% and a molecular weight of 362.33 g/mol (product reference). It is soluble in water (≥25.25 mg/mL), DMSO (≥22.7 mg/mL), and ethanol (≥17.47 mg/mL, ultrasonic-assisted). Storage at –20°C is required for stability; working solutions should be freshly prepared. Recommended in vitro concentrations range from 2 to 100 μM, depending on cell type and endpoint. In vivo dosing spans 2.5–80 mg/kg/day, via i.p., oral, or i.v. administration. Typical study durations are 14–28 days for stroke and osteoporosis models. For comprehensive experimental guidance, see the official APExBIO protocol.

Conclusion & Outlook

Catalpol is a validated, multi-target iridoid glycoside for neuroprotection and inflammation-centric disease models. Its molecular actions—NF-κB, NLRP3, and VEGF-PI3K/AKT pathway modulation—are reproducible and supported by quantitative animal and cellular studies. While clinical translation requires further investigation, catalpol remains a critical research tool for dissecting neuroinflammation, angiogenesis, and osteoprotection mechanisms. For updated mechanistic and workflow insights, this article expands upon prior APExBIO and literature reviews, providing a structured foundation for advanced translational research (Catalpol N1352).